医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Bruker Introduces New Products for Preclinical Imaging at WMIC 2014

2014年09月17日 PM10:21
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

At the 2014 World Molecular Imaging Congress (WMIC, www.wmis.org), Bruker today introduces new products for improved performance and customer experience in preclinical imaging, and announces related achievements:

SkyScan™ 1278, the world's fastest, low-dose, high-resolution micro-CT for preclinical imaging. (Pho ...

SkyScan™ 1278, the world’s fastest, low-dose, high-resolution micro-CT for preclinical imaging. (Photo: Business Wire)

NEW PRODUCT: SkyScan™ 1278, the world’s fastest, low-dose, high-resolution micro-CT: With the launch of the next-generation SkyScan 1278 micro-CT system for in vivo X-ray computed tomography, Bruker is addressing the latest needs of preclinical imaging scientists striving to reduce the radiation dose used in animal studies, while maintaining highest image quality. As part of the development, Bruker has created a new micro-CT spatial beam shaper, which reduces the absorbed dose by up to five times, while maintaining high quality image output.

The SkyScan 1278 has a highly sensitive flat-panel detector that is able to deliver images of mouse heart and lung activities even without a contrast agent. Such images allow the user to explore cardiac and respiratory function, while reducing animal stress and the cost of the study. A full-body animal scan can take 8 seconds or less, reducing run times and increasing the speed of data collection.

FIRST CUSTOMER INSTALLATION: Bruker announces the first customer installation of its MPI PreClinical, a preclinical Magnetic Particle Imaging (MPI) scanner, at the University Medical Center Hamburg-Eppendorf (UKE), Germany. Significantly, this marks the first time that MPI technology has been delivered in a commercial system. Preclinical MPI is an entirely new technology for in vivo imaging of small animals used in translational research.

The new MPI PreClinical was announced in 2013 and is the result of Bruker’s collaboration with Royal Philips (NYSE: PHG, AEX: PHIA). It combines Bruker’s leadership in preclinical imaging with Philips’ strength in medical imaging. MPI was invented by scientists at Philips and uses the detection of magnetic iron-oxide nanoparticles injected into the bloodstream to produce three-dimensional images at millisecond intervals, providing the potential for real-time 3D imaging in vivo. MPI’s high time-resolution allows researchers to investigate a range of dynamic issues, e.g. in cardiovascular research, which cannot be studied using other techniques.

NEW PRODUCT: BioSpec 21T Ultra-high Field MRI with CryoProbe Bruker introduces the BioSpec® 210/11, a new 21 Tesla ultra-high field MRI with CryoProbe™ for small animal Magnetic Resonance Imaging (MRI). As in vivo investigation shifts from organ and tissue imaging to cellular and molecular research, a significant boost in sensitivity and resolution is required. With the unique 21T MRI, Bruker customers can set new performance benchmarks and gain new insights in preclinical research.

The BioSpec 210/11 is based on Bruker’s proven 21 Tesla 11 cm USR™ magnet that is already successfully used in FT-mass spectrometry. UltraShield™ magnet technology reduces magnetic stray fields, while Bruker’s active refrigeration technology virtually eliminates cryogen refills, reducing down-time and user maintenance efforts.

NEW PCI CENTER: Bruker has enjoyed a long-term partnership with the Singapore Bioimaging Consortium (SBIC), and the new SBIC-Bruker Preclinical Imaging (PCI) Center in Singapore consolidates bio-imaging capabilities to promote innovation in biological research. The PCI facility, due to open in October 2014, will provide advanced demonstration, training and applications support for Bruker’s industry-leading preclinical portfolio and multi-modal imaging platforms. By combining PCI technologies and modalities, the center will play a key role in promoting the application of complementary imaging information.

Wulf I. Jung, Ph.D., President of Bruker’s Preclinical Imaging division, stated: “At WMIC 2014, we continue our Innovation with Integrity to enable the success of our customers. With differentiated, high performance products we enable novel preclinical imaging research and gain access to new markets, while maintaining our excellent reputation in the scientific research community.”

About Bruker Corporation

Bruker (NASDAQ: BRKR) is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for in vitro diagnostics, industrial and applied analysis.

For more information on Bruker’s Preclinical Imaging division, please visit www.bruker.com/preclinicalimaging.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140917005787/en/

CONTACT

Bruker Corporation
Media Contact:
Dr. Thorsten Thiel,
+49 (721) 5161–6500
Director of Marketing Communications
thorsten.thiel@bruker.com
or
Investor
Contact:

Joshua Young, +1 978-663-3660, ext. 1479
Vice
President, Investor Relations
joshua.young@bruker.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表